Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide

  • US 9,284,280 B2
  • Filed: 01/22/2014
  • Issued: 03/15/2016
  • Est. Priority Date: 06/26/2009
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating diabetic neuropathy, diabetic gangrene, peripheral circulatory disturbance, chronic arterial occlusion, intermittent claudication, scleroderma, thrombosis, pulmonary hypertension, myocardial infarction, angina, glomerulonephritis, diabetic nephropathy, chronic renal failure, bronchial asthma, interstitial pneumonia (pulmonary fibrosis), chronic obstructive pulmonary disease, inflammatory bowel disease, or symptoms associated with spinal canal stenosis, comprising the step of administering, as an active ingredient to a subject, a crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ

  • ;

    9.4 degrees, 9.8 degrees, 17.2 degrees and 19.4 degrees, wherein the X-ray powder diffraction diagram is obtained by using Cu Kα

    radiation.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×